Vice-President Underlines Iran’s Success in Production of Pneumococcal Vaccine
8:05 - January 03, 2024

Vice-President Underlines Iran’s Success in Production of Pneumococcal Vaccine

TEHRAN (ANA)- Iranian Vice-President for Science, Technology and Knowledge-Based Economy Rouhollah Deqani Firouzabadi said that the country’s scientists have developed the pneumococcal vaccine which inactivates 13 strains of bacteria.
News ID : 4678

“Iran is the second country that enjoys access to the pneumococcal vaccine which inactivates 13 strains of bacteria,” Dehqani Firouzabadi said.

“We hope to make the pneumococcal vaccine available to people in the next decade after clinical studies,” he added, noting that these upcoming projects will save nearly 280 million euros for the country.

PREVNAR 13 (usually called PCV13, PCV, Pneumococcal conjugate or Pneumococcal on your baby's immunization record) is given to babies, starting at 2 months, and ending at or soon after their 1st birthday, at 2, 4, 6, and 12-15 months of age, to protect against 13 common strains of pneumococcal bacteria.

There are three pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20). The different vaccines are recommended for different people based on age and medical status.

Your health care provider can help you determine which type of pneumococcal conjugate vaccine, and how many doses, you should receive.

4155/v

 

Send comment